Big Pharma’s retreat: Is NHS pricing behind investor pullbacks? 😔
Big Pharma’s retreat: Is NHS pricing behind investor pullbacks? 😔
Cikk tartalma röviden
Relations between Big Pharma and the UK government are deteriorating, with Eli Lilly's CEO criticizing the UK for poor drug pricing. Major pharmaceutical companies like AstraZeneca and Merck are pulling back investments, citing an uncompetitive environment. The UK spends less on medicines compared to other developed nations, relying heavily on generic drugs. The government’s pricing mechanisms, including NICE and the Voluntary Scheme for Branded Medicines Pricing, are seen as limiting. Experts suggest that the UK needs to improve its attractiveness for pharmaceutical investments through better tax incentives and public funding.
AI Médiaelemzés
A Mediaverzum mesterséges intelligencia motorjának automatikus kiértékelése
Hangulat/Élmény
Feszült / Nyugtalanító
Részrehajlás/Elfogultság
Nem meghatározható
Nyelvi nehézség
Átlagos / Normál
Kifejezések Érzelmi Töltete
Negatív kontextus
worst, pressure, scrapping, underfunding, urgent
Központi kifejezések
growing, uncompetitive, important, sustainable, efficient